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ABSTRACT
Retroviral replication proceeds through an obligate
integrated DNA provirus, making retroviral vectors
attractive vehicles for human gene-therapy. Though
most of the host cell genome is available for inte-
gration, the process of integration site selection is
not random. Retroviruses differ in their choice of
chromatin-associated features and also prefer par-
ticular nucleotide sequences at the point of inser-
tion. Lentiviruses including HIV-1 preferentially in-
tegrate within the bodies of active genes, whereas
the prototypical gammaretrovirus Moloney murine
leukemia virus (MoMLV) favors strong enhancers
and active gene promoter regions. Integration is
catalyzed by the viral integrase protein, and recent
research has demonstrated that HIV-1 and MoMLV
targeting preferences are in large part guided by
integrase-interacting host factors (LEDGF/p75 for
HIV-1 and BET proteins for MoMLV) that tether viral
intasomes to chromatin. In each case, the selectiv-
ity of epigenetic marks on histones recognized by
the protein tether helps to determine the integration
distribution.Incontrast,nucleotidepreferencesatin-
tegration sites seem to be governed by the ability for
the integrase protein to locally bend the DNA duplex
for pairwise insertion of the viral DNA ends. We dis-
cuss approaches to alter integration site selection
that could potentially improve the safety of retroviral
vectors in the clinic.
INTRODUCTION
Retroviral replication requires the covalent integration of
the reverse transcribed viral genome into the host cell chro-
matin. The integrated form of the virus, referred to as the
provirus, provides a template for viral gene expression. Be-
cause the provirus is an integral part of the host genome,
retroviruses persist in the host for the lifetime of the in-
fected cell. This trait of irreversible integration makes retro-
viruses particularly attractive vehicles for human-based ge-
netic therapy (1).
Although most of the host cell genome is amenable to
integration (2), retroviral integration is not a random pro-
cess (3), with several factors influencing integration site se-
lectivity. There are seven different retroviral genera––alpha
throughepsilon,lentiandspuma––andtheselectionofhost
DNA sequence and chromatin-associated features seems
to largely follow genera-specific patterns (4,5). For exam-
ples, lentiviruses including HIV-1 prefer to integrate within
the bodies of active genes located within gene dense re-
gions of chromosomes (6), while gammaretroviruses such
as Moloney murine leukemia virus (MoMLV) display bias
for integrating in the vicinity of strong enhancers, active
gene promoters and associated CpG islands (7–9). The
deltaretrovirus human T-lymphotropic virus type 1 and the
alpharetrovirus avian sarcoma-leukosis virus (ASLV) each
display a pattern that differs from HIV-1 and MoMLV, as
neither shows a strong preference for active genes or tran-
scription start sites (TSSs) (4,10). The betaretrovirus mouse
mammary tumorvirus(MMTV)seemstheleastselectiveof
all, displaying an integration pattern on the genomic level
that is basically indistinguishable from random (11,12).
Studies of the mechanisms of retroviral integration have
revealed two key players that determine integration site se-
lection: the retroviral integrase (IN) protein and cognate
cellular binding partners (13,14). In the case of lentivi-
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ral INs, integration site targeting is in large part guided
by the cellular chromatin binding protein lens epithelium-
derived growth factor (LEDGF)/p75, which facilitates in-
tegration into active gene bodies (15–18). More recent stud-
ies have identified the bromo- and extra-terminal domain
(BET) proteins (bromodomain (BRD) proteins 2, 3 and
4) as the main cellular binding partners of MoMLV IN
anddemonstratedtheirroleinpromotingefficientMoMLV
integration near TSSs (19–21). Collectively, these findings
have provided clues as to why different retroviruses ex-
hibit markedly distinct integration site selectivity. Although
retroviruses from the other five genera show less dramatic
targeting of chromatin-associated features than do either
the lentiviruses or gammaretroviruses, we nonetheless ex-
pectthattheseINproteinsalsointeractwithspecificnuclear
factors to facilitate virus integration.
The significance of integration site selection has been
highlighted by studies that have used retroviral vectors in
human gene-therapy. Retroviruses present efficient vehicles
for the delivery of therapeutic genes due to their trait of
stable DNA integration and because they are amenable
to pseudotyping with a variety of envelope glycoproteins
(1,22,23). In particular, MoMLV-based vectors have been
successfully utilized in the treatment of primary immunod-
eficiencies (24,25). However, adverse effects associated with
integrationofMoMLV-basedvectorsnearproto-oncogenes
were observed in these clinical trials (25–28). Therefore, un-
derstanding the underlying mechanisms for integration site
specificity could lead to the development of safer vectors
for human gene-therapy. The recent identification of BET
proteins as principal binding partners of MoMLV IN of-
fers a new means to understand and address this problem.
The present review compares the mechanisms of action of
LEDGF/p75 and BET proteins in their ability to navigate
HIV-1 and MoMLV integration to select chromatin sites
and the implications for human gene-therapy.
INTEGRATION: CATALYTIC MECHANISM AND TAR-
GET SITE SELECTION
Retroviral IN exhibits two distinct catalytic activities,
termed 3  processing and strand transfer, to covalently in-
sert the viral DNA into the host genome. Productive 3 
processing involves the cleavage of a dinucleotide from the
3  ends of the viral DNA, yielding invariant CAOH-3  se-
quences. During the following strand transfer reaction, IN
uses these 3 -hydroxyl groups to generate a staggered cut
in complementary strands of the target DNA and con-
comitantly join the viral DNA ends to the host genome
(29,30). The different retroviral IN proteins recognize scis-
sile phosphodiester bonds in target DNA that are separated
by 4–6 bp for strand transfer. The single-strand gaps in the
DNA recombination intermediate are repaired by cellular
enzymes, which accordingly yield 4–6 bp duplications of
target DNA flanking the integrated provirus. In infected
cells, IN functions in the context of a large nucleoprotein
complex called the preintegration complex (PIC), which in
addition to IN and viral DNA is comprised of a number of
viral and cellular proteins.
X-ray crystal structures of the spumaviral prototype
foamy virus (PFV) IN in complex with viral and target
DNA substrates have provided a major breakthrough for
understanding the mechanism of integration (31,32). One
key feature observed in the functional complex is that the
target DNA is significantly kinked to optimally position
IN active sites for the pair-wise strand transfer events.
These findings augmented earlier biochemical data (33–
37) showing that IN favors integration into DNA accep-
tor sites that display inherent bendability, including nucle-
osomal DNA wrapped around core histones. In particular,
the widened major groove, where nucleosomal DNA is rel-
atively distorted, appears to be preferentially targeted by
retroviral INs. Retroviral INs additionally exhibit a prefer-
ence for weakly conserved palindromic sequences that cen-
ter around the staggered cut in target DNA (3,38–41). It is
logical that these sequences are only weakly conserved, as
strong nucleotide sequence specificity would be disadvan-
tageous for viral fitness since this would limit the distribu-
tion of proviral sites suitable for optimal gene expression.
Accordingly, the majority of contacts between PFV IN and
target DNA in the crystal structures are mediated through
the phosphodiester backbone (31).
Recentresearchhasindicatedthatthenatureofthepalin-
dromic sequence in large part underlies the bendability of
thesubstrateatsitesofviralDNAjoining.Inparticular,the
preferred PFV integration site (-3)KWK↓VYRBMWM(6)
(written using International Union of Biochemistry base
codes; the arrow marks the position of viral DNA plus-
strand insertion and the underline notes the target site du-
plication, which is 4 bp for PFV) (42) preferentially har-
bors the YR dinucleotide at the center of the integration
site. The varying combinations of purine (R)/pyrimidine
(Y) dinucleotides possess inherently different base stack-
ing propensity and hence flexibility: YR and RY are the
most and least distortable, respectively, while RR and YY
fall in between (43). Retroviral IN proteins harbor three
common domains: the zinc-chelating N-terminal domain
(NTD), central catalytic core domain (CCD) that harbors
the enzyme active site and C-terminal domain (CTD) (re-
viewed in 44). Because PFV IN amino acids Ala188 in
the CCD and Arg329 in the CTD interact with the eight
bases of the target DNA consensus nucleotide signature
that abut the central YR, the DNA palindrome represents
preferentially bendable sequences that result from PFV IN-
base interactions and the centrally flexible YR sequence
(31). Similar scenarios are likely for the other retroviruses.
Recent analysis of the consensus HIV-1 integration site
(-3)TDG↓(G/V)TWA(C/B)CHA(7) highlighted the dinu-
cleotide signature (0)RYXRY(4) at its center. Though en-
riched in rigid RY dinucleotides at first glance, this pattern
actuallyensuresforrelativelyflexiblesequencesoverlapping
the center of the presumed DNA bend: Y at the center X
yields YY and YR at nucleotide positions 1 and 2 and at 2
and 3, respectively, whereas R in the center yields YR and
RR at these respective positions. Due to the lack of HIV-1
IN-DNA structures, less is known about the details of IN-
target DNA contacts that abut these central flexible mo-
tifs than is known for PFV IN. Nevertheless, mutagenesis
studies indicate that HIV-1 IN CCD residue Ser119, like its
Ala188 analog in PFV IN, interacts with the bases that lie
threepositionsupstreamfromthepointsofviralDNAjoin-
ing (45).Nucleic Acids Research, 2014, Vol. 42, No. 16 10211
LEDGF/P75 AND HIV-1 INTEGRATION
LEDGF/p75 was identified as an HIV-1 IN binding pro-
tein using different proteomic screens, including mass spec-
trometry (MS)-based analysis of cellular factors associated
withectopicallyexpressedINinhumancellsandbyyeast2-
hybrid (46–49). Because LEDGF/p75 knockdown signifi-
cantlyreducedthesteady-statelevelofectopicallyexpressed
HIV-1 IN, the host factor appeared to be the principal cel-
lular binding partner of the viral protein in human cells
(50,51).
LEDGF/p75 is a ubiquitous cellular protein. It was ini-
tiallydiscoveredasahumantranscriptionalcoactivator(52)
and has been shown to move around the nucleus of living
cellsby interacting withchromatin in a hop/scan mode that
is common among transcription factors (53). LEDGF/p75
also interacts with a number of cellular proteins including
JPO2(54,55),Cdc7-activatorofS-phasekinase(ASK)(56),
the ‘domesticated’ transposase pogZ (57) and menin, which
linksLEDGF/p75withmixed-lineageleukemia(MLL)his-
tonemethyltransferaseandresultsinMLL-dependenttran-
scription and leukemic transformation (58).
The structural organization of LEDGF/p75 (Figure 1A)
reveals an N-terminal PWWP domain, a basic-type nu-
clear localization signal, two AT-hook DNA binding mo-
tifs and three highly charged regions (CR1–3) that allow
this protein to tightly engage chromatin throughout the
cell cycle (59,60). The C-terminal region contains a domain
that is termed the IN binding domain (IBD) for its ability
to directly interact with HIV-1 IN (61). LEDGF/p75 be-
longs to the hepatoma-derived growth factor related pro-
tein (HRP) family that comprises five additional members
(HDGF, HRP1–3 and LEDGF/p52). HRP2 is the only
otherknowncellularproteinthatcontainsbothanIBDand
PWWPdomain(Figure1A).Theotherfamilymembers,in-
cludingthesmalleralternativelysplicedisoformofLEDGF
(LEDGF/p52), lack the IBD and thus fail to interact with
HIV-1 IN (50).
LEDGF/p75 binds tightly to a number of lentiviral INs
but fails to interact with INs from the other retroviral gen-
era (62–64). Accordingly, in vitro assays with purified INs
have revealed that LEDGF/p75 significantly stimulated the
strand transfer activities of lentiviral but not of other retro-
viralINs(47,60,61,64).Initiallyitwasunclearastowhether
LEDGF/p75 also promoted efficient HIV-1 integration in
cells,assignificantknockdownofLEDGF/p75eitherfailed
to reduce infectiousHIV-1 titer (62) or yielded only ∼2-fold
reductionsinintegration(65,66).However,parallelfindings
indicated that residual amounts of chromatin-associated
LEDGF/p75,whichcouldpersistamongcellclonesdespite
an overall efficient level of knockdown, were sufficient to
support near wild-type levels of HIV-1 infection and in-
tegration (67). Consistent with this finding, studies using
LEDGF/p75 knockout cells revealed 5 to 80-fold defects
in HIV-1 titer associated with ∼2 to 12-fold reductions in
integration (16–18,68). The integration defect of the un-
gulate lentivirus equine infectious anemia virus (EIAV) in
mouse knockout cells was reportedly >50-fold (16). Signifi-
cant inhibitory effects on HIV-1 replication were also ob-
served in cells engineered to express constructs that con-
tained the IBD but lacked the N-terminal elements present
in full length LEDGF/p75 that confer chromatin binding
(67,69,70). The monitoring of viral replication intermedi-
ates has pinpointed that LEDGF/p75 depletion or overex-
pression of dominant-interfering IBD constructs does not
significantly affect HIV-1 reverse transcription but instead
selectively impairs integration. Collectively, the in vitro and
cell culture experiments conclusively demonstrated a stimu-
latory role for LEDGF/p75 on lentiviral DNA integration.
Genome-wideintegration sitemapping experimentswere
carried out to explore the role of LEDGF/p75 in integra-
tion site selectivity. The first line of evidence for its role
in HIV-1 target site selection emerged from the analysis of
LEDGF/p75 knockdown cells, where significantly reduced
frequencies of HIV-1 integration into active genes were
observed even though these cells supported normal levels
of HIV-1 infection (15,62). Subsequent experiments using
LEDGF/p75 knockout cells corroborated these findings
and extended them to show that a significant percentage of
HIV-1 proviruses were aberrantly located near TSSs in the
absence of the host factor (16,17). Furthermore, chimeric
constructs that replaced the N-terminal chromatin-binding
portions of LEDGF/p75 with the chromatin binding re-
gions of other proteins supported efficient HIV-1 infection
(71–73) and retargeted integration away from active genes
and toward the sites preferentially bound by the heterol-
ogous chromatin binding domains (72–74). For example,
replacing the N-terminal PWWP domain and AT hooks
of LEDGF/p75 with a plant homeodomain (PHD) finger
redirectedHIV-1DNAintegrationtoTSSs.Integrationfre-
quencies within 2.5 kb of TSSs were 50.3 and 3.8% in the
presence of the ectopically expressed fusion and wild-type
LEDGF/p75 proteins, respectively (72). Similar use of the
chromobox homolog 1 (CBX1) and heterochromatin pro-
tein 1 (HP1) alpha chromatin binding modules imposed a
genomic pattern of HIV-1 integration that resembled ran-
dom (72,73).
Mapping of the LEDGF/p75 chromatin-binding profile
along the Encyclopedia of DNA Elements has revealed a
preference for binding active transcription units, which par-
alleled the enhanced HIV-1 integration frequencies at these
locations (75). These observations extended the prior find-
ing that LEDGF/p75 was required for the chromosomal
association of ectopically expressed HIV-1 IN in human
cells (50). Collectively, these findings provide strong evi-
dencethatLEDGF/p75tethersPICstoactivetranscription
units during HIV-1 integration. Although LEDGF/p75
can potently stimulate HIV-1 IN catalytic function in vitro
(47,60,61,76,77), it is somewhat unclear if the host factor
provides this function during virus infection. LEDGF/p75
immunoprecipitationcanrecoverPICactivityfrominfected
cell extracts, indicating that the IN-binding factor is a com-
ponent of the HIV-1 PIC (62). Interestingly, the wild-type
level of HIV-1 PIC activity is maintained in samples iso-
lated from LEDGF/p75 knockout cells (17). Therefore,
LEDGF/p75 may provide chromatin-tethering function to
lentiviral PICs without contributing to the formation of the
catalytically active intasome.
The frequency of HIV-1 integration into active transcrip-
tion units remained greater than random in LEDGF/p75
knockout cells (16–18), suggesting a potential role for other
cellular proteins in integration targeting. In particular, a10212 Nucleic Acids Research, 2014, Vol. 42, No. 16
Figure 1. Features and domain organization of LEDGF/p75, HRP2 and BET proteins. (A) The N-terminal region of LEDGF/p75, which contains a
PWWP domain, charged regions (CR) 1–3, nuclear localization signal (NLS), and AT-hooks, interacts with chromatin. Similar to LEDGF/p75, HRP2
contains an N-terminal PWWP domain and AT-hooks. HRP2 has an additional domain, termed the homology region III (HR3) that is conserved in
multiple HRP2 homologs as well as in LEDGF/p75. The C-terminal regions of both proteins exhibit the IBD that directly interacts with lentiviral INs.
(B) The BET proteins consist of BRD2, 3, 4 and T (not pictured). Whereas BRD3 is expressed as a single isoform, BRD2 is expressed as four isoforms
(isoform 1 is pictured) and BRD4 as three isoforms (isoforms A and C are pictured; as compared to isoform C, isoform B harbors a unique 75 amino acid
C-terminal tail that interacts with condensing II complexes; 183). Known domains and their respective start and end amino acids numbers are indicated.
Two N-terminal bromodomains (BD I and II) and motifs A and B collectively contribute to high affinity chromatin binding. In the C-terminal region of
the BET proteins, the conserved ET domain interacts with multiple proteins including MoMLV IN. Other domains include the SEED domain, which is
present in all BET proteins, the BID, which is present in all BRD4 isoforms, and the CTM, which is unique to BRD4 isoform A.
role for HRP2 was investigated due to its close struc-
tural similarity with LEDGF/p75 (Figure 1A). In vitro as-
says with purified proteins demonstrated that HRP2 tightly
binds HIV-1 IN and significantly stimulates its catalytic
function (61). However, unlike LEDGF/p75, HRP2 does
not remain bound to chromatin throughout the cell cycle
(78). HRP2 depletion in cells containing normal levels of
LEDGF/p75 did not have any detectable effect on HIV-
1 titer or integration targeting (18,67,79,80). When HRP2
was depleted in LEDGF/p75 knockout cells, a further re-
duction in the preference of HIV-1 for integrating into ac-
tive genes was observed (80,81). These findings argue that
LEDGF/p75 is the principal cellular determinant for tar-
geting HIV-1 integration to active transcriptional units and
that HRP2 could play a secondary role. Notably, the pref-
erence for HIV-1 to integrate into active genes remained
greater than random in LEDGF/HRP2 double knockout
cells, suggesting that subsidiary targeting roles might exist
for as of yet undefined lentiviral IN-binding proteins (80).
BET PROTEINS AND MOMLV INTEGRATION
The observation that the distribution of MoMLV
proviruses along chromatin differed markedly from
HIV-1 suggested that MoMLV IN relies on cellular
binding partners other than LEDGF/p75 for integration
target-site selection. Initial experiments with yeast 2-hybrid
screening revealed a number of potential binding part-
ners of MoMLV IN, including BRD2 (82). More recent
MS-based proteomic analysis of human cellular proteins
that co-purified with recombinantly expressed MoMLV IN
identified BET proteins (BRD2, 3 and 4) as main binding
partners of the viral protein (19,21).
BRD2, 3, 4 and T belong to the BET protein family,
which in turn is a part of the extended BET family thatNucleic Acids Research, 2014, Vol. 42, No. 16 10213
includes BRD1, 7, 8 and 9. BRD2, 3 and 4 are ubiq-
uitously expressed, whereas BRDT is only expressed in
testis. BET proteins have been implicated in transcription,
DNA replication and cell cycle control (reviewed in 83,84).
They exhibit several conserved domains and motifs (Fig-
ure 1B). Two N-terminal bromodomains (BD-I and BD-
II) bind acetylated H3 and H4 tails on chromatin (85,86).
Two conserved motifs, A and B, are positively charged and
could contribute to DNA binding (87). An additional ba-
sic residue-enriched interaction domain (BID) has recently
been described for BRD4 and shown to interact with cellu-
lar factor p53 (88). While this domain has not been con-
firmed in BRD2 or BRD3, sequence alignments identify
a similar region corresponding to BRD2 residues 533–584
thatis44%identicaland66%homologousconsideringcon-
servative amino acid substitutions. A short 17-residue re-
gion of BRD3 (amino acids 476–493) shows homology to
the N-terminal part of the BID, though this could be due
to the overlapping B motif. The C-terminal extra-terminal
(ET) and SEED (Ser/Glu/Asp-rich region) domains that
are present throughout the BET proteins directly engage
various cellular proteins including transcription factors,
chromatin modifying proteins, histone modifying enzymes
and also interact with different viral proteins (reviewed in
84). BRD3 exhibits a single isoform, whereas BRD2 and
BRD4 are expressed in several isoforms (Figure 1B). In ad-
dition to the above structural elements, BRD4 isoform C
contains a C-terminal motif (CTM) that has been shown to
bind a number of cellular proteins and also plays a role in
HIV-1 latency (89–91).
Notably,BETproteinsplayanactiveroleinthelifecycles
of different viral families including Papillomaviridae, Her-
pesviridae, Polyomaviridae and Retroviridae. In addition to
regulating transcriptional activation of Epstein–Barr virus,
Kaposi’s sarcoma-associated herpesvirus (KSHV), and pa-
pillomavirus, they can repress the transcription of papillo-
mavirus E6 and E7 promoters, aid papillomavirus episomal
maintenance and genome segregation, and control reacti-
vation of latent HIV-1 reservoirs (reviewed in 83,92; also
see 90,91,93–96). Of these, the most pertinent to this re-
view is the role of BET proteins in tethering papillomavirus
genomestocondensedmitoticchromosomes(93,94),which
is mediated through the binding of BRD4 with papillo-
mavirus E2 protein (93,97,98). In particular, the C-terminal
DNA-binding domain of E2 protein binds viral DNA,
whereas the N-terminal transactivation domain of the E2
protein directly interacts with the C-terminal region of
BRD4. In turn, this nucleoprotein complex is tethered to
host chromatin by the two N-terminal bromodomains of
BRD4,whichassociateswithacetylatedlysinesinthetailre-
gions of histones H3 and H4 (83,86,99,100). This tethering
mechanism ensures papillomavirus episomal maintenance
by coupling the viral genomes to host chromosomes during
mitosis, and subsequent distribution to daughter cells after
cell division.
Investigation into the role of BET proteins during
MoMLV integration has also revealed a bimodal tether-
ing mechanism. Biochemical assays with purified proteins
haverevealeddirect,high affinityinteractionsbetweenBET
proteins and MoMLV IN as well as between BET pro-
teins and mononucleosomes (19–21,87). Furthermore, pu-
rified recombinant BRD4-C (19,87) and, to a lesser degree,
the isolated ET domains of BRD2, 3 and 4 (20), signifi-
cantly enhanced the pair-wise or concerted integration ac-
tivity of MoMLV IN in vitro (19,20,87). BET protein bind-
ing and enzymatic stimulation was specific for IN proteins
derived from gammaretroviruses and not for other retro-
viruses (19–21). The stimulation of MoMLV IN in vitro
activity was mediated through the bimodal interaction of
BRD4 with naked DNA and MoMLV IN (87). Interest-
ingly, the levels of stimulation of MoMLV IN integration
activities by BRD4 were comparable to that of HIV-1 IN
by LEDGF/p75 (19). In addition, MoMLV IN and BET
proteinshavebeenshowntocolocalizeincellnuclei(20,21).
Small molecules JQ-1 and I-BET, which specifically im-
pair interactions of all three BET proteins with cognate hi-
stone marks (86,101), were exploited to examine the role of
BET proteins in MoMLV replication. These inhibitors se-
lectively impaired MoMLV but not HIV-1 replication (19–
21). Furthermore, the analysis of replication intermediates
revealed that the inhibition of BET proteins with JQ-1 im-
paired MoMLV integration in a dose dependent manner,
yieldinginhibitoryconcentration50%(IC50)valuesof∼50–
100 nM (19,20). Taken together, in vitro and cell culture
experiments indicate that the BET proteins function for
MoMLV like LEDGF/p75 does for HIV-1: specific chro-
matin tethers that interact with PICs by binding their cog-
nate IN and potentially stimulating its enzymatic function.
The chromatin binding sites of BET proteins have been
mapped using ChIP-Seq experiments (100), which when
compared with retroviral integration sites showed a posi-
tive correlation with MoMLV but not with HIV-1 or ASLV
(19,21). In particular, MoMLV exhibited a strong prefer-
ence for promoters associated with the binding sites of
BET proteins. Treatment with JQ-1 and I-BET was used
to experimentally examine the roles of BET proteins in
MoMLV integration site selectivity (19,20). Alternatively,
the effect of concurrent down-regulation of BRD2, 3 and
4 by a pool of short interfering (si) RNAs was investigated
(19). Treatment with inhibitors or siRNA significantly re-
duced the characteristic preference of MoMLV for inte-
grating near TSSs. For example, in the absence of JQ-1,
MoMLV integration in HEK293T cells was strongly fa-
vored (39% integration events) within 2-kb regions of Ref-
Seq TSSs, whereas after JQ-1 treatment this frequency was
reduced in a dose-dependent manner to 11% at the highest
dose tested (19). A complementary approach investigated
an artificial fusion protein that contained the N-terminal
chromatin binding segment of LEDGF/p75 (amino acids
1–324) and the C-terminal BRD4(ET/SEED) segment that
interacts with MoMLV IN (21). Ectopic expression of the
chimericLEDGF(1–324)/BRD4(ET/SEED)proteinretar-
geted MoMLV integration away from TSSs and toward
the bodies of active genes, a pattern that is reminiscent
of LEDGF/p75-mediated lentiviral integration. Taken to-
gether, these studies (19–21) have dissected the role of BET
proteins in targeting MoMLV integration near TSSs.10214 Nucleic Acids Research, 2014, Vol. 42, No. 16
STRUCTURAL ASPECTS OF HIV-1 IN-LEDGF/P75
AND MOMLV IN-BET PROTEIN INTERACTIONS
Highly conserved structural features of retroviral IN pro-
teins include the catalytic triad of Asp, Asp and Glu (DDE)
residues that coordinates a pair of essential Mg2+ ions
during 3  processing and strand transfer (32) and the Zn-
binding motif (HH-CC type) in the NTD that contributes
to IN multimerization and DNA binding (102,103)( F i g -
ure 2A). Furthermore, the crystal structure of the PFV IN-
viral DNA complex, or intasome (103), has enabled plau-
sible molecular modeling studies of HIV-1 IN interactions
withitsDNAsubstrates(45,104–107). Thesestudiesinturn
suggest that the overall architectures of different retrovi-
ral intasomes may exhibit significant resemblance with the
PFV structure.However,despite potentialoverall similarity
among different retroviral intasome structures, studies with
LEDGF/p75 and BET proteins have revealed that retro-
viruses from different genera markedly differ in their inter-
actions with their cognate cellular binding partners.
The principal LEDGF/p75 IBD binding determinant on
HIV-1 IN is the CCD (108), although the NTD is addi-
tionally required for high affinity binding (50,77,109). A
shortinterhelicalloopfromtheIBDdocksintoanarrow,V-
shapedcavityattheinterfaceoftwoINCCDmoleculesand
establishes functionally critical hydrogen bonds between
LEDGF/p75 hotspot residue Asp366 and the backbone
amides of IN residues Glu170 and His171 (Figure 2Ba n d
C)(108,110).TheLEDGF/p75bindingpocketisconserved
amongst lentiviral INs, whereas the corresponding seg-
ments in other retroviral INs exhibit significant differences
(108). While the dimeric organization of the PFV CCDs is
present in the functional intasome, the two interacting sub-
units of the PFV CCD create an ∼90◦ angle compared with
an acute angle observed for the lentiviral CCDs. Addition-
ally,INCCDresiduesthatinteractwithLEDGF/p75show
greater degrees of conservation amongst lentiviral as com-
pared to the other retroviral proteins despite the fact that
all retroviral IN CCDs contain the invariant DDE catalytic
triad (64,109,111;a l s os e eF i g u r e2B).
Alignment of the primary sequences of different retrovi-
ral INs has revealed that the C-terminal 28 amino acid tail
of MoMLV IN is unique to the gammaretroviruses (112)
(Figure 2D). For a long time, the functional significance of
this tail had remained enigmatic, as various deletions of it
did not significantly affect MoMLV infectivity (113). Re-
cent reports have clarified that the role of the C-terminal
tail is to directly bind the BET proteins (21,87,112). Nu-
clear magnetic resonance, MS-based protein footprinting
and site-directed mutagenesis experiments have collectively
identified that the MoMLV IN C-terminal tail (amino acid
residues 386–405) directly mediates interactions with BET
proteins (21,87,112). This region of MoMLV IN was dis-
ordered in the unliganded CTD structure but became or-
dered in the presence of the BRD3 ET domain (112). Im-
portantly, C-terminal truncation mutants of recombinant
MoMLV IN lacking all or part of the C-terminal tail ex-
hibited markedly impaired interaction with BRD4, but re-
tainedwild-typelevelsofINcatalyticactivities(87).Consis-
tentwiththisobservation,theMoMLVC-terminaldeletion
mutant 1–385 lost the ability to interact with BRD2, 3 and
4, and a 24-mer peptide composed of IN residues 386–408
(Figure 2D) disrupted the interaction between full length
IN and the BRD3 ET domain in vitro (112). Somewhat un-
clear is the extent to which MoMLV IN regions outside
the C-terminal tail might contribute to BET protein bind-
ing. Whereas Sharma et al. did not detect any binding to a
CTD deletion mutant of MoMLV IN (19), Gupta et al. re-
ported that an N-terminal deletion mutation that removed
the NTD and first 50 residues of the CCD significantly re-
duced binding despite the fact that this construct harbored
an intact C-terminal tail (20). Results of Ala-scanning mu-
tagenesisledtheseinvestigatorstosuggestthatresiduesthat
compose CCD  helix 6 contributed to BET protein bind-
ing (20). In summary, whereas numerous groups have high-
lighted the importance of the MoMLV IN C-terminal tail
region in BET protein binding (19–21,87,112), additional
workisrequiredtohelpclarifytheextenttowhichtheCCD
contributes to overall binding affinity.
There is precedence for integration-mediated targeting
through the C-terminal tail of an IN protein and a cog-
natechromatinbindingprotein.Retrotransposonsareanal-
ogous to retroviruses, with the exception that they lack
an extracellular phase of replication. To avoid inactiva-
tion of essential genes, the integration of these elements is
tightly linked to subsets of genomic loci. In the case of the
yeast Ty5 retrotransposon, integration is favored into het-
erochromatin (114). Ty5 integration targeting is mediated
by a 6-mer peptide at the IN C-terminus and the host het-
erochromatin protein Sir4p (115). With now two examples
of retroelement integration targeting mediated between the
C-terminal tail of IN and a cognate chromatin binding pro-
tein, we predict that other viruses/transposons will also be
found to take advantage of this design to steer the integra-
tion of their reverse transcripts.
Recent truncation mutagenesis and MS-based protein
footprinting experiments have identified the ET domain
of BET proteins as the primary interface interacting with
MoMLV IN (19–21,87). The BID region of BRD4 con-
tributed additional interactions and increased the bind-
ing affinity to MoMLV IN (87). Complementary NMR
and mutagenesis experiments have defined the MoMLV
IN binding sites on the BRD4 ET domain in more detail
(20,21,87). The majority of interacting residues are located
on ET helices 2 and 3 and the loop connecting these two
helices (Figure 2E). These studies have provided structural
clues for the specificity and high affinity binding between
BRD4 and MoMLV IN. The determination of the struc-
ture of the MoMLV IN CTD bound to a BRD ET domain
isexpectedtoprovidefurthervaluabledetailsabouthowthe
viral and cellular proteins recognize each other.
Interestingly, whereas expression of the LEDGF/p75
IBD in target cells can potently inhibit HIV-1 infection and
integration (67,69,70), over expressing the IBD of BRD2
(residues 640–801) stimulated MoMLV infection and in-
tegration ∼2-fold (20). Although the reason behind this
rather dramatic difference is unclear, we speculate it may
lie in the mode of host factor-IN binding. As discussed,
the LEDGF/p75 IBD engages IN at the CCD-CCD dimer
interface (108)( F i g u r e2C), which is also the binding site
of a potent class of small molecule inhibitors that promote
IN multimerization and inhibit HIV-1 IN catalysis in vitroNucleic Acids Research, 2014, Vol. 42, No. 16 10215
Figure 2. HIV-1 and MoMLV IN similarities and differences. (A) Features and domain organization of HIV-1 and MoMLV INs. Retroviral INs consist of
three conserved domains, the N-terminal domain (NTD, yellow), the catalytic core domain (CCD, gray) and the C-terminal domain (CTD, blue). Shown
in red is the conserved amino acids of the catalytic triad (DDE) that coordinates Mg2+ and is responsible for 3  processing and strand transfer activities.
Also shown in blue letters is the Zn binding motif (HH-CC type) that helps to mediate IN multimerization. (B) Sequence alignment of mid region sections
of retroviral IN CCDs from HIV-1 strain NL4–3 (GenBank accession code M19921.2), HIV-2 strain ROD (M15390), feline immunodeficiency virus (FIV,
M25381.1), equine infectious leukemia virus (EIAV, M16575.1) and MoMLV (NC 001501.1). Invariant residues across retroviral INs are shown in red
(glutamic acid of the DDE catalytic triad) and blue (lysine that mediates binding to viral DNA; 103,184). Residues highlighted in black are identical
across this alignment, whereas those highlighted in gray are conserved in minimally three of the sequences based on the following chemical groupings:
G, A, S, T, P; M, V, L, I; F, Y, W; D, E, N, Q; K, R, H; C (185). IN residues that interact with the LEDGF/p75 IBD are highlighted by the nature of
the contact: s for side chain and b for backbone (64). The rectangle highlights residues that compose the 4/5 connector region that lies between CCD
 helices 4 and 5 and mediates several key contacts with LEDGF/p75 (108). (C) Ribbon diagram of the crystal structure of a dimer of the HIV-1 IN
CCD (cyan and green) bound to the LEDGF/p75 IBD (gray). The carboxylate side chain of LEDGF/p75 residue Asp366 hydrogen bonds with the
backbone amides of IN residues Glu170 and His171. The adjacent LEDGF/p75 residue Ile365 (not shown) predominantly interacts with the cyan IN
molecule through hydrophobic contacts. (D) Sequence alignment of the C-terminal tail regions of gammaretroviral INs from the following full-length
molecular clones: MoMLV, MLV from the AKV mouse strain (J01998.1), feline leukemia virus (FeLV, NC 001940.1), gibbon ape leukemia virus (GaLV,
NC 001885.2) and reticuloendotheliosis virus (REV) strain GD1210 (KF709431.1). Among these viruses, MoMLV and FeLV have been shown to favor
TSSs during integration (7,186). These IN proteins have also been shown to bind BET proteins in vitro (19–21). Below the alignment is the consensus
Wx xxpxxPLb b xR sequence, where p stands for small polar (S or T) residue, b stands for basic (R, K, or H),   stands for small hydrophobic (M,
V, I, or L) and x refers to a position that is not conserved across the alignment. (E) Ribbon diagram of the NMR structure of BRD4 ET domain, with
residues in red implicated in interacting with the MoMLV IN CTD as determined by chemical shift perturbations. These interactions were predominantly
observed in helices 2 and 3 and the short loop connecting them (indicated by an arrow).
(116–118). Conceivably, over expressed IBD protein in tar-
get cells, which functionally inhibits viral DNA integration,
could similarly inhibit IN catalysis. BET proteins by con-
trast engage a functionally inert aspect of gammaretroviral
IN structure, the disordered C-terminal tail (87,112). Ac-
cordingly,weconcludethatforcedexpressionofaBETpro-
tein IBD in target cells is unlikely to deregulate IN catalytic
function. The purified ET domains of BRD2, 3 and 4 could
moreover stimulate MoMLV IN strand transfer activity in
vitro (20), indicating that the protein domains might have
similar IN stimulatory activity during virus infection. Con-
sistent with this interpretation, immunoprecipitation of ec-
topically expressed green fluorescent protein fusions to ei-
ther BRD2 or BRD4 co-precipitated IN from cells infected10216 Nucleic Acids Research, 2014, Vol. 42, No. 16
with MoMLV (20). The analysis of HIV-1 and MoMLV
PICs derived from cells over expressing the LEDGF/p75
or BET protein IBD should reveal if different levels of IN
catalytic function determine the differences observed in vi-
ral titer under these infection conditions.
LEDGF/P75 AND BET PROTEINS NAVIGATE RETRO-
VIRAL PICS TO SELECT CHROMATIN MARKS
The tethering roles of LEDGF/p75 and BET proteins im-
ply that the interactions of these cellular proteins with cog-
natechromatinfeaturesinturninfluencesretroviralintegra-
tionsiteselectivity.Indeed,LEDGF/p75recognizeshistone
H3tailscontainingtrimethylatedLys36(H3K36me3)(119–
121), which is an epigenetic marker for active transcription
units and positively correlates with HIV-1 integration sites
(73,122;a l s os e eF i g u r e3A). On the other hand, BET pro-
teins preferentially engage certain acetylated H3 and H4
peptidesincludingH3K9ac,H3K14ac,H3K27ac,H4K5ac,
H4K8ac, H4K12ac and H4K16ac (123–126) that are en-
riched near TSSs and proto-oncogenes, and are preferred
sites for MLV integration (87,122;a l s os e eF i g u r e3).
The N-terminal PWWP domain is the key determi-
nant for the site selective association of LEDGF/p75 with
chromatin. HIV-1 integration sites in the presence of wild
type LEDGF/p75 differed substantially from those gener-
ated in the presence of truncation mutants that lacked the
PWWPdomain(127).NMRstructuresoftheLEDGF/p75
PWWP domain revealed two distinct functional interfaces:
a well-defined hydrophobic pocket that interacts with the
H3K36me3histonetail,andanadjacentbasicinterfacethat
non-specifically engages DNA (120,121). Interestingly, the
LEDGF/p75 PWWP domain exhibited low binding affini-
ties for both an isolated H3K36me3 peptide and for naked
DNA, whereas it interacted tightly with mononucleosomes
that contained a tri-methyl-lysine analogue at position 36
of H3. These results indicate that cooperative binding of
LEDGF/p75 with both the H3K36me3 tail and nucleo-
somal DNA is essential for the tight and site-selective as-
sociation of LEDGF/p75 with chromatin (120). Indeed,
mutations introduced in either the hydrophobic pocket or
the basic surface significantly compromised the ability of
LEDGF/p75 to both associate with chromatin and stim-
ulate HIV-1 integration (128). These findings collectively
indicate that LEDGF/p75-mediated navigation of lentivi-
ral PICs to actively transcribed genes provides IN with
increased access to nucleosomal DNA, which are the fa-
vored sites for integration both in vitro and in infected cells
(35,36,129).
Similar to HIV-1, MoMLV integration sites are periodi-
cally distributed on nucleosomal DNA along cellular chro-
mosomes (122). Furthermore, a recent study has suggested
that akin to LEDGF/p75, BET proteins engage both DNA
wrapped around the histone core and their cognate epige-
netic marks to tightly bind chromatin (87). For example,
BRD4 bound purified native mononucleosomes with sig-
nificantly higher affinity than either naked DNA or isolated
acetylated peptides. The two N-terminal bromodomains of
BET proteins have been shown to interact with a number of
acetylated H3 and H4 peptides but not with their unmod-
ified counterparts (123–125). Furthermore, peptides con-
taining multiple acetylated sites were particularly favored
(123,130). Yet, the tightest binding affinity reported to date,
∼3 M, which was seen between BRD4 BD-I and a tetra-
acetylated H4 substrate, is a comparatively weak interac-
tion (130). Two conserved motifs, A and B, which are lo-
cated adjacent to the bromodomains (Figure 1B), exhibit
highly basic interfaces and contribute to BET protein bind-
ing to DNA. However, BRD4 interacted with naked DNA
with a relatively low binding affinity (∼2 M) compared
with the much tighter binding (Kd ∼60 nM) detected with
native mononucleosomes (87). Thus the cooperative bind-
ing to both cognate histone marks and nucleosomal DNA
could be a generic mechanism employed by various chro-
matin tethers to allow their tight interactions with select re-
gions of chromatin.
Recent reports that significantly extended the number of
unique MoMLV integration sites analyzed (∼3.9 million)
have yielded novel insight into the mechanism of MoMLV
PIC targeting (8,9). For example, approximately half of all
MoMLV integrations occurred within 1.6–2.0% of the hu-
man genome (8). Close examination revealed that strong
enhancers and active promoters are superior predictors of
MoMLV integration as compared to TSSs. Clustered tran-
scription factor binding sites essentially comprise enhancer
elements, which function to form a platform for transcrip-
tional regulatory complex recruitment (reviewed in 131). In
terms of MoMLV integration, the greatest enrichment was
found in enhancers that are characterized by H3K4me1,
H3K4me2, H3Kme3, H3K27ac and H3K9ac marks (8,9).
However, the precise hierarchy of favored histone modifi-
cations varied among cell type (8,9), which likely recapitu-
lates the observation that the activities of many enhancers
are cell-type specific (132). Independent studies suggested
that enhancers are the major source of BRD4-dependent
transcriptional activation (133) and that genes that are reg-
ulatedbystrongenhancersareparticularlysensitivetoBET
inhibition (134). Because BET proteins are unlikely to di-
rectlyengagemethylatedhistonetails,theirassociationwith
strong enhancers could be mediated through direct interac-
tions with H3K27ac and H3K9ac marks and/or with con-
gregated heterologous transcription factors (134).
Although the specificity of favored enhancer-associated
epigeneticmarkcanvaryamongcelltype,asignificantnum-
ber, about one-third, of targeted H3K4me1 marks in CD4+
T cells and CD34+ hematopoietic stem cells overlapped (9).
Therefore,thecorrelationofintegrationsitesinonecelltype
to mapped positions of histone epigenetic mark in a second
cell type can yield overall global patterns of MoMLV site
selectivity in response to BET protein disruption, for exam-
plethroughtargetedsiRNAdepletionofhostfactorsorJQ-
1 treatment (21,87)( F i g u r e3B). The observation that JQ-1
treatmentorconcurrentBETproteindepletionsignificantly
reduced MoMLV integration frequencies at sites associated
with enhancer and promoter-associated histone marks is
consistent with the BET protein-mediated tethering mecha-
nism of MoMLV integration (9,21,87). As the genomic oc-
cupancies of BRD2, 3 and 4 are non identical (135), fur-
therexperimentationthatcorrelatesparticularBETprotein
binding sites and histone epigenetic marks across cell type
will help to better understand the detailed mechanisms that
underlie MoMLV integration site selectivity.Nucleic Acids Research, 2014, Vol. 42, No. 16 10217
Figure 3. Heatmaps depicting relationships between retroviral integration frequencies and histone post-translational modifications. For both panels (A
and B), the integration site data sets are shown in columns with the histone post-translational modifications in the rows labeled to the left. The rela-
tionship between the integration site frequencies relative to matched random controls for each of the annotated histone post-translational modification
was quantified by the receiver operator characteristic (ROC) curve area method. The color key depicts enrichment or depletion of the annotated feature
near integration sites. P-values are for individual integration site datasets compared to match random controls, ***P < 0.001; **P < 0.01; *P < 0.05.
(A) Integration frequencies of different retroviruses including MoMLV, HIV-1 and ASLV. (B) Integration frequencies of MoMLV with respect to histone
post-translational modifications following treatment with either DMSO or the JQ-1 (500 nM) inhibitor. Figure adapted from (87).
Despite the fact that LEDGF/p75 and BET proteins rec-
ognize distinct histone marks and bind different retrovi-
ral INs, the overall bimodal interaction (Figure 4)u s e dt o
tether retroviral PICs to chromatin seems to be a common
mechanism. HIV-1 and MoMLV depend on these cellu-
lar factors for effective and timely access for the integra-
tion of their viral DNAs into host chromosomes. Relatively
rapid targeting to chromatin acceptor sites for IN-mediated
strand transfer is likely crucial for virus survival, as the
propensity for unintegrated DNA to be either degraded or
modified by cellular proteins increases over time. For exam-
ple, the two viral DNA ends can be ligated to form 2-long
terminal repeat (LTR)-containing circles, which are a dead
end for the viruses because they cannot support replication10218 Nucleic Acids Research, 2014, Vol. 42, No. 16
Figure 4. Model depicting the bimodal interactions of LEDGF/p75 and
BET proteins with corresponding HIV-1 and MoMLV intasomes and
mononucleosomes containing select histone marks. (A) LEDGF/p75 (de-
picted in blue) is able to bind selectively and with high affinity to mononu-
cleosomes through the cooperative binding of the PWWP domain with
the H3K36me3 histone tail and the three charge regions (CR1–3) with the
DNA (shown in red) wrapped around the histones (shown in gray). The
C-terminal IBD of LEDGF/p75 is able to directly engage the HIV-1 in-
tasome (depicted with a tetramer of HIV-1 IN in orange and viral DNA,
in a dark red single line). (B) A BRD protein (depicted in green) is able
to bind selectively and with high affinity to mononucleosomes through the
cooperative binding of the dual bromodomains with acetylated H3 and
H4 histone tails (H4 acetylation depicted here) and motifs A and B with
DNA (shown in red) wrapped around the histones (shown in gray). The
C-terminal region of the BET protein is able to engage the MoMLV inta-
some (depicted with a tetramer of MoMLV IN in purple and viral DNA
in a dark red single line) through its extra terminal (ET) domain, which
binds to the C-terminal tail of MoMLV IN. The SEED domain does not
directly contribute to these interactions but may play an accessory role in
complex stability (87).
(136). Another key reason for HIV-1 and MoMLV to uti-
lize LEDGF/p75 and BET proteins is to preferentially po-
sition their viral DNA into transcriptionally active regions
of the host genome. Having such a distribution of proviral
DNA should facilitate viral gene expression. Therefore, the
ability of LEDGF/p75 and BET proteins to both enhance
integration efficiency and preferentially target the site of in-
tegrationintofavorableregionsforHIV-1andMoMLVcol-
lectively ensures for effective viral replication.
OTHER VIRAL AND CELLULAR FACTORS AFFECT-
ING INTEGRATION SITE SELECTIVITY
HIV-1 and MoMLV take different paths en route to the
host chromosomal sites for integration. Lentiviruses can ef-
ficiently infect non-dividing cells, and their PICs can ac-
cordingly traverse through the nuclear pore complexes that
perforate the interphase nuclear envelope (137 for review).
MoMLV PICs lack this ability, and gammaretroviruses ac-
cordingly rely on mitosis and nuclear envelope dissolution
to access cell chromosomes (138). Therefore, it is not sur-
prising that a number of cellular proteins that are involved
innucleartransporthavealsobeenshowntoinfluenceHIV-
1 but not MoMLV integration. The key HIV-1 determinant
that governs PIC nuclear import is the viral capsid (CA)
protein,whichisexpressedaspartoftheGagstructuralpre-
cursor protein (137,139).
Genome-wide siRNA screens have identified cell host
factors that are important for efficient HIV-1 infection
(140–142). Of these hits, nucleoporin (NUP) proteins
NUP358 (also known as RanBP2) and NUP153, as well as
thebeta-karyopherintransportin-3/TNPO3(alsoknownas
TRN-SR2), have been scrutinized for their roles in the early
steps of HIV-1 replication (143–148). Depletion of these
cellular proteins could not only adversely affect PIC nu-
clear localization and integration efficiency, but also alter
the pattern of HIV-1 proviruses along chromatin. In partic-
ular, RanBP2, TNPO3 or NUP153 depletion resulted in re-
duced HIV-1 integration frequencies in gene dense regions
of chromosomes (144,146,147). As noted earlier, IN is the
key viral protein that governs integration site selection (13).
To investigate potential roles for other viral proteins in inte-
grationsiteselection,chimericHIV-1virusescontainingthe
substitution of MoMLV Gag counterparts were previously
examined.Interestingly,thesechimericvirusesdisplayedre-
duced integration frequencies in gene rich regions, which
suggested a Gag-dependent role in integration site target-
ing (13,144,146). Moreover, a single missense mutation that
resulted in an N74D change in HIV-1 CA counteracted the
preference for HIV-1 to integrate into gene-rich regions of
chromosomes (146,149). Because the mutant virus with an
N74D CA substitution efficiently infected cells that were
depleted for RanBP2, TNPO3 or NUP153, its novel inte-
gration profile may be linked to an alternative pathway of
PICnuclearimport.Collectively,thesefindingssuggestthat
the route taken by HIV-1 PICs during nuclear import is
directly linked to integration site selection. Accordingly, a
two-step model has been proposed, where during nuclear
entry the nuclear pore components direct HIV-1 PICs to-
ward regions of high gene density, after which the PICs
engage LEDGF/p75 to gain access to active gene bodies
(144,146). Consistent with this interpretation, results of flu-
orescent imaging indicate that HIV-1 has the propensity to
integrate into chromatin that is associated with the nuclear
periphery (150).
The interaction of MoMLV IN with BET proteins is the
best studied example of a virus-host interaction that de-
termines gammaretroviral integration target site selection.Nucleic Acids Research, 2014, Vol. 42, No. 16 10219
However, it is noteworthy that even with potent inhibition
of BET proteins by JQ-1, which blocks their interactions
with cognate histone marks, integration events at TSSs,
while significantly reduced, were still substantially higher
than random or when compared to HIV-1 (19,21). These
findings suggest that additional host and/or viral factors
could contribute to the integration pattern characteristic of
MoMLV. One component of MoMLV PICs is the p12 Gag
protein, which has been shown to mediate the association
between PICs and condensed mitotic chromosomes (151).
However,mutationsthatalteredp12interactionswithchro-
matin had no detectable effects on MoMLV integration
target site selection (152). Identification of new players in
MoMLV integration target site selection will not only help
to elucidate the molecular mechanisms of MoMLV integra-
tion, but will also inform ongoing efforts to develop retro-
viral vectors for human gene-therapy.
IMPLICATIONS FOR DEVELOPING RETROVIRAL
VECTORS FOR HUMAN GENE-THERAPY
Retroviral vectors have been successfully used in clini-
cal human gene-therapy to rectify monogenic disorders
by stably expressing the therapeutic transgene in patients.
Replication-defective vectors have been derived from vari-
ous retroviral genera, such as gammaretrovirus, lentivirus
and spumavirus, as well as from retotransposons (re-
viewed in 153). The widespread success of first-generation
gammaretrovirus-basedvectorsforhumangene-therapyre-
sulted from their use in the correction of primary immun-
odeficiencies, such as X-linked severe combined immunod-
eficiency (SCID-X1), adenosine deaminase-SCID (ADA-
SCID), Wiskott–Aldrich syndrome (WAS) and X-linked
chronic granulomatous disease (CGD) (reviewed in 154–
157). The therapeutic concept for utilizing gammaretroviral
MoMLV-based vectors was first successfully demonstrated
for autologous hematopoietic stem cell (HSC) gene therapy
for SCID-X1 (24). In separate clinical trials from 1999 to
2009, a total of 20 SCID-X1 patients underwent treatment
for a gene defect in interleukin 2 common gamma chain
(IL2c) using MoMLV-based HSC gene therapy (158). Au-
tologous CD34+ cells derived from patient bone marrow
were transduced ex vivo with MoMLV-based vectors car-
rying the IL2c transgene. Clinical benefits were achieved
in 17 of 20 patients who displayed transgene expression,
restorationofT-cellfunctionandlong-termimmunological
correction. Unfortunately, severe adverse events occurred
in five of the 20 patients, who developed leukemia (158).
The associated cancer in these patients was linked to the
insertion of MoMLV-based vectors near the LMO-2 proto-
oncogene in four instances and near the CCND2 proto-
oncogene in the remaining case (26–28). The integrations
led to MoMLV-LTR driven transcriptional upregulation of
the nearby proto-oncogenes (26–28). In separate studies for
thetreatmentofdifferentgeneticdiseases,suchasWASand
CGD, patients likewise have developed cancer (159–161).
Theadverseoutcomesfromtheseclinicaltrialshavehigh-
lighted the significance of exploring the molecular mech-
anisms of retroviral integration site selection for develop-
ing ‘safer’ retroviral vectors for human gene-therapy (162).
The genotoxicity associated with retroviral vector integra-
tion in the host genome can be explained by the follow-
ing mechanisms (also reviewed in 163–165): (i) activation
of host gene promoters by enhancers present in the viral
LTRs, leading to transcriptional activation and upregula-
tion of host genes, (ii) transcriptional read-through of the
host gene resulting in aberrant and/or chimeric transcripts
whoseexpressioncanresultinadverseeffectsand(iii)dereg-
ulation of host gene expression due to cryptic splicing or
premature polyadenylation of host genes due to RNA ele-
ments present in the viral LTR. Interestingly, ∼0.12% of all
MoMLV integration occurred in the vicinity of the LMO-2
proto-oncogene in CD34+ cells whereas integration in this
region was not detected in CD4+ cells (9). These observa-
tions highlight the utility of determining retroviral integra-
tion site distributions in clinically relevant target cells prior
to in vivo transplantation.
In depth analysis of the SCID-X1 gene-therapy trial
has established that the initiation of leukemia was due
to the transcriptional activation of proto-oncogenes by
MoMLV vector LTRs (26–28). Additionally, it was shown
that the leukemic T cell clones accumulated secondary
genetic aberrations such as translocations and deletions,
consistent with the ‘multiple-hit’ hypothesis of oncogene-
sis (166,167). Thus, integration of retroviral vectors near
proto-oncogenes or growth control genes can prime the
transformation process and lead to the expansion of aber-
rant clones by clonal dominance. In light of these points,
second-generation retroviral vectors have been developed.
These self-inactivating (SIN) vectors bear deletions in the
U3 region of the viral LTR, which contains the viral
enhancer/promoter elements. The SIN vectors have dis-
played a safer profile in in vitro genotoxicity assays (168–
170) and have been used in recent clinical trials for SCID-
X1, ADA-SCID, WAS and X-CGD (171).
Recent identification of the key role of BET proteins
for MoMLV integration site selectivity has opened up
new paths to modulate gene-therapy applications with the
goal to suppress unwanted genotoxicity. For example, JQ-
1 treatment has been shown in a cell line model to re-
duce the frequency of MoMLV integration in the vicin-
ity of proto-oncogenes (19,87). Accordingly, CD34+ cells
could be treated with BET protein inhibitors during ex
vivo transduction with MoMLV-based vectors, though ini-
tial work would need to determine integration frequencies
near proto-oncogenes in comparison to previously utilized
cell line models and additionally address any potential toxi-
city of the small molecules in CD34+ cells. Ongoing clinical
trials to determine the safety profiles of second generation
BET inhibitors such as I-BET762 (172) and OTX015 (173)
in the treatment of human cancers should help inform as
to which molecules could have utility with MoMLV-based
gene-therapy vectors.
An alternative approach to counteract the genotoxicity
of MoMLV-based vectors would be to utilize chimeric cel-
lular proteins to redirect MoMLV integration away from
proto-oncogenes and toward ‘safer’ chromosomal sites. For
example, a proof of concept study showed that ectopi-
cally expressed LEDGF(1–324)/BRD4(ET/SEED) redi-
rected MoMLV integration away from TSSs and toward
active genes (21). However, the potential clinical applica-
tions of BET protein-mediated MoMLV retargeting are10220 Nucleic Acids Research, 2014, Vol. 42, No. 16
fairly unclear. One significant drawback is the requirement
of having the chimeric tethering factor in the target cell,
presumably in advance of challenge with the therapeutic
retroviral vector. A more direct approach might be to uti-
lize MoMLV IN C-terminal tail deletion mutant vectors.
While various deletions or mutations of the MoMLV IN
C-terminal tail markedly compromised IN binding to BET
proteins(19,21,87,112),theterminaltailregionisnotessen-
tialforcatalyticactivitiesoftheenzymeinvitro(174–176)or
for virus replication in cell culture (113,177–179). MoMLV
mutants with deleted or altered IN C-terminal tails dis-
playedmarkedlyreducedintegrationfrequenciesnearTSSs,
CpG islands and BET protein-binding sites (112). For ex-
ample, integration frequencies for wild-type and mutant
MLVs within 1 kb of TSSs averaged ∼12 and ∼2.5%, re-
spectively. Yet, the residual preference of mutant MoMLVs
for this chromatin region was still evident when compared
to HIV-1. One potential explanation for this observation
is the residual affinity of BET proteins to bind C-terminal
truncation mutants of MoMLV IN (20). Alternatively, sec-
ondary chromatin-associated factors might arise in the ab-
sence of BET protein engagement, as occurs for HIV-1 in
the absence of LEDGF/p75 protein (16,17).
The problems encountered with MoMLV-based vectors
have prompted the development of HIV-derived lentivi-
ral vectors. As discussed above, lentiviral vectors unlike
MoMLV are able to transduce both dividing and non-
dividing differentiated cells with high efficiency (180). Even
more importantly, HIV-1 integration is disfavored near
TSSs and proto-oncogenes, which could reduce the risks of
transcriptionalactivation.Inarecentclinicaltrialinvolving
one patient, a lentiviral vector was successfully employed
to correct beta thalassemia major (181). Interestingly, in
this case the vector integrated within the HMGA2 proto-
oncogene, however the respective cell clone expanded with-
out leukemic progression (181). Clinical trials with larger
number of individuals will allow assessing the risks versus
benefit ratios for the clinical utility of lentiviral vectors.
Electrostatic interactions between the HIV-1 IN NTD
and LEDGF/p75 IBD, which are important for the high
affinityinteraction,havebeenscrutinizedtoartificiallycon-
trol HIV-1 integration site selectivity (109,182). Reverse-
charged mutations were engineered at the interacting inter-
faces of both proteins to allow mutant HIV-1 IN to recog-
nize complementary mutant LEDGF/p75, but not the re-
spectivewild-typecounterparts.Thetransductionefficiency
of an optimized mutant IN vector, which was reduced to
∼10–20% compared with the wild-type vector in cells ex-
pressing wild-type LEDGF/p75, increased to ∼75% upon
ectopic expression of complementary reverse-engineered
LEDGF/p75(182).Theapplicationofthisapproachcanbe
extended to develop heterologous fusion proteins contain-
ing the mutant LEDGF/p75 IBD and desired chromatin
tethering modules to control the HIV-1 integration pat-
tern. Nevertheless, customized lentiviral retargeting strate-
gies suffer the common drawback of ectopic expression of
the retargeting factor in susceptible target cells (182). Clini-
cal trials could potentially compare modified MoMLV and
HIV-1 based vectors to MMTV-based constructs, as this
betaretrovirus reportedly targets host chromatin in a ran-
dom fashion (11,12).
SUMMARY
Recent research has clarified the molecular mechanisms
that underlie integration site selection of retroviruses. The
propensity for weakly conserved palindromic sequences at
the sites of integration seemingly reflects IN-target DNA
interactions that preferentially bend the DNA to position
it near the two IN active sites within the functional inta-
some complex. Of the six profiled retroviral genera––the
genome-wide distribution of epsilonretrovirus integration
hasyettobereported––gammaretrovirusesandlentiviruses
display the most distinctive profiles. Whereas the interac-
tion between LEDGF/p75 and HIV-1 IN targets integra-
tion into active gene bodies, MoMLV IN engages BET pro-
teins to integrate in the vicinity of strong enhancers and the
TSSs of active gene promoters. Though many differences
existbetweenthesetwosystems,includingtheregionsofthe
IN protein that interact with its cognate host cellular pro-
teinandtheresultingepigeneticmarktowhichtheintasome
complex is tethered, the overall concept of bimodal tether-
ing of PIC-associated IN to specific regions of chromatin is
strikingly similar and parallel findings in the related area
of retrotransposon integration targeting. For retroviruses
these interactions likely help to situate the provirus within
well-expressed regions of the host genome. These discov-
eries have sprung novel initiatives toward controlling the
specificity of retroviral DNA integration, in particular for
the field of human gene-therapy. For example, the potential
targeting of MoMLV vectors away from TSSs and onco-
genesbygeneratingclinicalvectorsthatlacktheC-terminal
tail of MoMLV IN and hence do not engage BET proteins
mayprovelessgenotoxicthanpreviousMoMLV-basedclin-
ical vectors. The field of retroviral integration site target-
ing is quickly evolving, with exciting advances on the basic
mechanism and utility of virus-derived vectors for treating
human genetic disorders expectedly forthcoming.
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